Hillhouse Capital Management - PROTEOSTASIS THERAPEUTICS IN ownership

Quarter-by-quarter ownership
Hillhouse Capital Management ownership history of PROTEOSTASIS THERAPEUTICS IN
ValueSharesWeighting
Q3 2018$2,087,000
-13.6%
865,9230.0%0.06%
+36.6%
Q2 2018$2,416,000
-41.3%
865,9230.0%0.04%
-43.8%
Q1 2018$4,113,000
-18.5%
865,9230.0%0.07%
-15.1%
Q4 2017$5,048,000
+177.7%
865,9230.0%0.09%
+186.7%
Q3 2017$1,818,000
-55.1%
865,9230.0%0.03%
-51.6%
Q2 2017$4,053,000
-40.2%
865,9230.0%0.06%
-52.7%
Q1 2017$6,772,000
-36.2%
865,9230.0%0.13%
-44.7%
Q4 2016$10,616,000
-10.8%
865,923
+13.4%
0.24%
-2.5%
Q3 2016$11,907,000763,7900.24%
Other shareholders
PROTEOSTASIS THERAPEUTICS IN shareholders Q3 2023
NameSharesValueWeighting ↓
VHCP Management III, LLC 722,890$911,0000.53%
GREAT POINT PARTNERS LLC 3,500,000$4,410,0000.44%
NEA Management Company, LLC 5,556,778$7,002,0000.36%
SECTORAL ASSET MANAGEMENT INC 2,050,328$2,583,0000.31%
HARBOURVEST PARTNERS LLC 440,627$555,0000.20%
VHCP Management II, LLC 427,110$538,0000.16%
Endurant Capital Management LP 130,600$165,0000.06%
ALGERT GLOBAL LLC 64,300$81,0000.05%
Bain Capital Public Equity Management, LLC 231,418$292,0000.03%
Kazazian Asset Management, LLC 14,436$18,0000.02%
View complete list of PROTEOSTASIS THERAPEUTICS IN shareholders